IRX-2

Summary

IRX-2 is an investigational biological immunotherapy consisting of a defined mixture of natural human cytokines. It has been studied primarily as a neoadjuvant or adjuvant immunotherapy for head and neck squamous cell carcinoma (HNSCC) and other solid tumors, aiming to reverse cancer-induced immune dysfunction and potentiate anti-tumor immunity. Clinical trials have demonstrated safety, immune biomarker changes, and signals of clinical benefit.

Mechanism of Action

IRX-2 is a natural cytokine mixture derived from activated human peripheral blood mononuclear cells (PBMCs) stimulated with phytohemagglutinin. It contains a defined combination of cytokines including IL-1β, IL-2, IL-6, IL-8, IFN-γ, TNF-α, and others. It acts by restoring immune function in tumor-bearing hosts: enhancing dendritic cell maturation and trafficking, promoting T-cell activation and proliferation, counteracting tumor-induced immune suppression, and augmenting innate and adaptive immune responses against tumor antigens.

Routes of Administration

Goals & Uses

• Neoadjuvant immunotherapy prior to surgeryPerioperative OncologyModerate
• Combination with checkpoint inhibitorsOncologyLow
• Restoration of cancer-induced immune suppressionImmunomodulationModerate
• Anti-tumor immunotherapy in HNSCCOncology / ImmunotherapyModerate

Contraindications

• Active uncontrolled infectionInfectious DiseaseHigh
• Organ transplant recipients on immunosuppressionTransplantHigh
• Active autoimmune diseaseAutoimmunityHigh

Adverse Effects

• Hypersensitivity reactionsImmunologicRare
• Flu-like symptomsSystemic/ImmunologicalCommon
• Cytokine release syndromeImmunologicRareSystemic inflammatory response from immune activation
• Injection site reactionsLocalCommon
• LymphadenopathyLymphoreticularUncommon

Drug Interactions

• PD-1/PD-L1 checkpoint inhibitorsLow
• Immunosuppressive agents (e.g., methotrexate, azathioprine)High
• CorticosteroidsModerate

Population Constraints

• Pediatric patientsAgeRelative
• Pregnant or lactating womenReproductiveRelative
• Patients with HIV or other immunodeficiencyImmunologicalRelative

Regulatory Status

• European UnionInvestigationalNo EMA marketing authorization; clinical trials conducted under national CTAs in EU member states.
• United StatesInvestigationalFDA Fast Track designation granted for HNSCC. IND active. Not approved for any indication.
• United KingdomInvestigationalNo MHRA approval. Investigational status only.

IRX-2 has received FDA Fast Track designation for treatment of head and neck squamous cell carcinoma. It remains investigational and has not received FDA, EMA, or MHRA marketing approval. Manufactured under controlled GMP conditions from human donor PBMCs.

Evidence & Sources

No sources recorded yet.